NeuroBo Pharmaceuticals Inc
(NRBO.O)NeuroBo Pharmaceuticals Inc chart This market's chart. This is a visual representation of the price action in the market, over a certain period of time. You can use this to help gauge a market’s performance.
- Costs and details
- Related markets
Minimum size 1
Margin 25%
Minimum stop distance 1
Minimum guaranteed stop distance 25.0%
22:30 - 05:00 (Singapore Local Time)
Your aggregate position in this market will be margined in the following tiers:
Tier | Position size | Margin |
1 | 0 - 3425 Shares | 25% |
2 | 3425 - 17125 Shares | 40% |
3 | 17125 - 30825 Shares | 60% |
4 | 30825 + Shares | 75% |
If your aggregate position is larger than Tier 1, your margin requirement will not be reduced by non-guaranteed stops.
Please note: we have tried to ensure that the information here is as accurate as possible, but it is intended for guidance only and any errors will not be binding on us.
Non-leveraged only
Unborrowable
Why IG?
Go long or short on over 13,000 shares
Get direct market access (DMA)
Trade share CFDs
Discover opportunity in-platform
Discover opportunity in-app
Open a free, no-risk demo account to stay on top of market movement and important events.
Reuters news feed
React to the latest company news and analysis in-platform, where you need it
Three types of alert
Be notified when a stock's price changes an amount, hits a level or meets your technical conditions
Economic calendar
Plan your trades around earnings announcements, dividend payments and more, with customisable alerts to remind you ahead of time
Real-time charts
Analyse price action on fast, reliable HTML5 charts with 25+ indicators
Reuters news feed
Three types of alert
Economic calendar
Real-time charts
More from IG:
You might be interested in…
Go long or short on over 13,000 share prices. Find out more about why you should choose IG.
Discover why so many clients choose us, and what makes us the world's No.1 provider of CFDs.1
Improve your trading skills by working through interactive courses on the IG Academy app.
1Based on revenue (published financial statements, October 2023)